NovaBay Pharmaceuticals, Inc. (NBY) |
|
2.29 0.27 (13.37%)
|
01-27 15:59 |
|
Open: |
1.98 |
Pre. Close: |
2.02 |
|
High:
|
2.31 |
Low:
|
1.98 |
|
Volume:
|
100,762 |
Market Cap:
|
4(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:46:31 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 3.1 One year: 3.62 |
| Support: |
Support1: 1.78 Support2: 1.24 |
| Resistance: |
Resistance1: 2.66 Resistance2: 3.1 |
| Pivot: |
2.16 |
| Moving Average: |
MA(5): 2.16 MA(20): 2.12
MA(100): 3.06  MA(250): 6.54 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 39.3 %D(3): 41.7 |
| RSI: |
RSI(14): 55.4 |
| 52-week: |
High: 12.94 Low: 0.18 |
| Average Vol(K): |
3-Month: 71 (K) 10-Days: 66 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ NBY ] has closed below upper band by 27.3%. Bollinger Bands are 66.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.31 - 2.33 |
2.33 - 2.34 |
|
Low:
|
1.95 - 1.97 |
1.97 - 1.98 |
|
Close:
|
2.26 - 2.29 |
2.29 - 2.31 |
|
Company Description |
|
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California. |
Headline News |
Wed, 25 Jan 2023
Niobay Metals Provides Update on Metallurgical Progress at the ... - Junior Mining Network
Tue, 17 Jan 2023
PhaseOne Health and NovaBay Pharmaceuticals to Expand ... - Business Wire
Fri, 30 Dec 2022
Why Silo Pharma Shares Are Trading Higher By Around 64%? Here ... - Investing.com UK
Wed, 30 Nov 2022
Healthcare Stocks Making Moves Wednesday: HZNP, CHEK, CGEN, AVDL, CNSP, ONCS, NBY, XFOR - InvestorsObserver
Wed, 16 Nov 2022
NovaBay Pharmaceuticals (NBY) Stock: 1-For-35 Reverse Split Goes Into Effect - Pulse 2.0
Tue, 15 Nov 2022
NBY stock falls as company announces reverse stock split (NYSE ... - Seeking Alpha
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
45 (M) |
| Shares Float |
35 (M) |
|
% Held by Insiders
|
21.1 (%) |
|
% Held by Institutions
|
2.6 (%) |
|
Shares Short
|
2,080 (K) |
|
Shares Short P.Month
|
1,940 (K) |
Stock Financials |
|
EPS
|
-0.18 |
|
EPS Est Next Qtl
|
-0.03 |
|
EPS Est This Year
|
-0.47 |
|
EPS Est Next Year
|
-0.1 |
|
Book Value (p.s.)
|
0.2 |
|
Profit Margin (%)
|
-96.8 |
|
Operating Margin (%)
|
-96.9 |
|
Return on Assets (ttm)
|
-31.7 |
|
Return on Equity (ttm)
|
-63.9 |
|
Qtrly Rev. Growth
|
-15.2 |
|
Gross Profit (p.s.)
|
0.13 |
|
Sales Per Share
|
0.17 |
|
EBITDA (p.s.)
|
-0.17 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-6 (M) |
|
Levered Free Cash Flow
|
-3 (M) |
Stock Valuations |
|
PE Ratio
|
-13.24 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
10.9 |
|
Price to Sales
|
13.42 |
|
Price to Cash Flow
|
-16.3 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
